Kite’s Christi Shaw, AbbVie’s Jag Dosanjh, and LexisNexis Risk Solution’s Liz Paulson earn top industry honors.
Gilead receives the rights to exclusively license EVOQ’s NanoDisc Technology to develop and commercialize immunotherapy products for rheumatoid arthritis and lupus.
Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.
The European Union’s health regulator has advised the use of antiviral treatments over monoclonal antibodies to treat COVID-19 in patients at risk of their condition worsening, citing concerns over decreasing effectiveness against newer virus variants.
Sobi North America, a unit of Swedish Orphan Biovitrum AB , said on Thursday the U.S. Food and Drug Administration authorized its arthritis drug for treatment of high-risk hospitalized COVID-19 patients.
Gilead’s hopes for an approval in hepatitis delta virus (HDV) infection and compensated liver disease will have to wait following an FDA rejection.
Gilead Sciences and MacroGenics entered into a licensing and collaboration pact worth up to $1.7 billion to develop a bispecific antibody to treat hematological cancers.
A federal judge in New York has frozen the assets of dozens of people and entities accused of operating a massive nationwide scheme to distribute counterfeit bottles of Gilead Sciences Inc. HIV drugs, including two alleged “kingpins.”
Two COVID-19 antibody therapies are no longer recommended by the World Health Organization (WHO), on the basis that Omicron and the variant’s latest offshoots have likely rendered them obsolete.
Gilead Sciences Inc.’s Trodelvy extended by 3.2 months the survival of patients with advanced stages of a common type of breast cancer, according to data released ahead of a presentation at a European cancer meeting on Friday.